Centurion BioPharma announced that a provisional patent application has been filed with the U.S. Patent and Trademark Office covering its unique albumin companion diagnostic (ACDx) for use alongside its albumin binding ultra-high potency LADR (Linker Activated Drug Release) drug candidates. The goal of ACDx is to identify patients with cancer who are most likely to benefit from treatment with the company's lead assets, LADR-7, LADR-8, LADR-9 and LADR-10 and from any other albumin-binding drugs the Company may generate in the future.
ACDx utilizes new imaging agents to radiolabel albumin and when used in combination with state-of-the art imaging techniques, allows for detection of albumin uptake and distribution in the patient's tumor. Since the LADR drug candidates are albumin-binding drugs, the company believes the response rates will be higher in the selected patients who test positive with this personalized medicine companion diagnostic.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"Our companion diagnostic will offer physicians the ability to determine a cancer patient's unique physiological tumor characteristics and to use these distinctions to select albumin-based LADR drug candidates that increase the likelihood of a successful outcome, while reducing the potential for possible adverse reactions," said Felix Kratz, PhD, Centurion BioPharma's Vice President of Drug Discovery and inventor of the companion diagnostic. "ACDx also has the potential to enhance the effectiveness of future clinical trials evaluating LADR -7, -8, -9 and -10 and to accelerate the development process and the time to market. We believe the co-development of our targeted LADR™ drug candidates along with this proprietary companion diagnostic will prove to be a successful strategy to expedite these novel, albumin-binding, ultra-high potency anti-cancer agents from the bench to the bedside."
“In the rapidly-evolving field of oncology, extensive resources are being devoted not only to the discovery and development of innovative drug regimens, but also to companion diagnostics to provide targeted therapies that better serve individual patients," said Eric Curtis, Centurion BioPharma's Chief Executive Officer and President. "The newly filed patent covers our internally developed ACDx technology, an innovative companion diagnostic that through continued development, would provide patients with a personalized approach to their treatment with our investigational LADR drug candidates. We believe ACDx strengthens Centurion's competitive advantages and affirms the ability of LADR to be studied in multiple tumor types, making our pipeline significantly more valuable to strategic partners."